Cefamandole Sodium Salt
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-03861 |
| CAS | 30034-03-8 |
| Molecular Weight | 484.48 |
| Molecular Formula | C18H17N6NaO5S2 |
| Purity | >95% |
Online Inquiry
Description
Cefamandole sodium is a second generation cephalosporin antibiotic.
Specification
| Related CAS | 34444-01-4 (free base) |
| Synonyms | Sodium Cefamandole |
| Storage | Store at -20°C |
| IUPAC Name | sodium;(6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| Canonical SMILES | CN1C(=NN=N1)SCC2=C(N3C(C(C3=O)NC(=O)C(C4=CC=CC=C4)O)SC2)C(=O)[O-].[Na+] |
| InChI | InChI=1S/C18H18N6O5S2.Na/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9;/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29);/q;+1/p-1/t11-,13-,16-;/m1./s1 |
| InChI Key | OJMNTWPPFNMOCJ-CFOLLTDRSA-M |
| Source | Semi-synthetic |
Properties
| Appearance | White to Off-white Powder |
| Antibiotic Activity Spectrum | Gram-positive bacteria; Gram-negative bacteria |
| Melting Point | >154°C |
| Solubility | Soluble in DMSO, Methanol, Water |
Reference Reading
1. Chemical stabilities of cefoperazone sodium and ceftazidime in 5% dextrose and 0.9% sodium chloride injections
V Das Gupta,C Bethea,M dela Torre J Clin Pharm Ther . 1988 Jun;13(3):199-205. doi: 10.1111/j.1365-2710.1988.tb00181.x.
The chemical stabilities of cefoperazone and ceftazidime solutions in 5% dextrose and 0.9% sodium chloride injections have been studied using high-performance liquid chromatography methods. The solutions of cefoperazone were stable for 8 days (loss in potency of less than 10%) at 25 degrees C, for at least 80 days at 5 degrees C and for at least 96 days at -10 degrees C. The ceftazidime solutions were stable for only 2 days at 25 degrees C, for 21 days at 5 degrees C (28 days in normal saline) and for 90 days at -10 degrees C. Thawing the frozen solutions using a microwave oven did not cause degradation.
2. Mild encephalopathy/encephalitis with a reversible splenial lesion (MERS): A report of five neonatal cases
Lei Chen,Juan Wang,Dan Sun,Suraj Baralc,Yuan-Peng Xia,Wen-Hong Chen,Zhi-Sheng Liu J Huazhong Univ Sci Technolog Med Sci . 2017 Jun;37(3):433-438. doi: 10.1007/s11596-017-1753-5.
Mild encephalopathy/encephalitis with a reversible splenial (MERS) lesion is a clinic-radiological entity. The clinical features of MERS in neonates are still not systemically reported. This paper presents five cases of MERS, and the up-to-date reviews of previously reported cases were collected and analyzed in the literature. Here we describe five cases clinically diagnosed with MERS. All of them were neonates and the average age was about 4 days. They were admitted for the common neurological symptoms such as hyperspasmia, poor reactivity and delirium. Auxiliary examinations during hospitalization also exhibited features in common. In this report, we reached following conclusions. Firstly, magnetic resonance imaging revealed solitary or comprehensive lesions in the splenium of corpus callosum, some of them extending to almost the whole corpus callosum. The lesions showed low intensity signal on T1-weighted images, homogeneously hyperintense signal on T2-weighted images, fluid-attenuated inversion recovery and diffusion-weighted images, and exhibited an obvious reduced diffusion on apparent diffusion coefficient map. Moreover, the lesions in the magnetic resonance imaging disappeared very quickly even prior to the clinical recovery. Secondly, all the cases depicted here suffered electrolyte disturbances especially hyponatremia which could be easily corrected. Lastly, all of the cases recovered quickly over one week to one month and majority of them exhibited signs of infections and normal electroencephalography.
3. Pharmacovigilance of cutaneous adverse drug reactions in associations with drugs and medical conditions: a retrospective study of hospitalized patients
Lei Zheng,Jing Yang,Yu-Yao Guan,Hao-Bin Jin BMC Pharmacol Toxicol . 2022 Aug 10;23(1):62. doi: 10.1186/s40360-022-00603-4.
Background:Cutaneous adverse drug reaction (CADR) is a common problem in clinical medication. This study aimed to investigate the correlation between clinical drug application and CADR occurrence as evidence for preventive strategies and rational clinical drug use.Methods:We analyzed the characteristics of CADRs of 858 patients admitted to Shandong Provincial Third Hospital from March 2007 to December 2018. The most significant drugs concerning the common skin symptoms and their significance to CADR were investigated by case-non-case and multiple logistic regression analyses.Results:A total of 266 drugs were involved in 858 cases of CADR. Among the ten most relevant medications, primarily antibiotics and herbal injections, and nutritional support drugs, potassium sodium dehydroandrographolide succinate injection, and cefoperazone sodium and sulbactam sodium injection were found to be 2.1 and 1.45 times statistically more prone to CADRs than to other adverse drug reactions (ADRs), respectively. The main route of administration was intravenous (63.16%), with oral administration accounting for 25.19%. There were 747 cases of ADR, 71 of severe ADR, 2 of new and severe ADRs, and 38 cases of new ADR. Overall, 100 cases of CADR exhibited abnormal alanine aminotransferase, aspartate aminotransferase, and serum creatinine levels. The predictive factors for severe CADR occurrence included allergy and smoking histories, cefoperazone sodium, sulbactam sodium injection, levofloxacin lactate and sodium chloride injection.Conclusions:Drug-induced CADR symptoms are commonly associated with other ARDs, predominantly rashes and pruritus, and are often accompanied by some medical conditions, especially liver and kidney damage. Detailed attention to a patient's primary diseases, allergy history, and drug safety profile could help prevent or reverse CADR in most patients.
4. Antibiotic activity in peritoneal dialysate
G Smith,J Humphries,J Bower,J Rubin Am J Kidney Dis . 1983 Nov;3(3):205-8. doi: 10.1016/s0272-6386(83)80063-8.
There are few studies investigating whether antibiotics added to 30% glucose concentrate preserve their activity in the delivered dialysate. Using a Drake-Willock proportioning system, samples were obtained from the "to" patient path at ten minutes after starting and at four hours. Samples were tested for minimal inhibitory dilution (MID) against Escherichia coli and Staphylococcus aureus. Antibiotics evaluated included amikacin, tobramycin, gentamicin, cephalothin, cefamandole, moxalactam, ampicillin, penicillin, carbenicillin, and vancomycin. In all antibiotics studied, similar MIDs were obtained at the ten-minute and four-hour samples. Compared to saline, dialysate significantly impaired the antibiotic activity (a difference of two or more tube dilutions) of all antimicrobial agents except amikacin and vancomycin.
Recommended Products
| BBF-01829 | Deoxynojirimycin | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
| BBF-03754 | CASTANOSPERMINE | Inquiry |
| BBF-02614 | Nystatin | Inquiry |
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
| BBF-05862 | Epirubicin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
